Carlos Fernández‐Teruel

Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study

Emiliano Calvo, Víctor Moreno, Michael Flynn et al. · Annals of Oncology · 2017 · 85 citations · Full text

Kinetic modelling of passive transport and active efflux of a fluoroquinolone across Caco-2 cells using a compartmental approach in NONMEM

Isabel González‐Álvarez, Carlos Fernández‐Teruel, Teresa Garrigues et al. · Xenobiotica · 2005 · 41 citations

Biophysical Modeling, Engineering, Cellular Physiology +17

<i>In situ</i>kinetic modelling of intestinal efflux in rats: functional characterization of segmental differences and correlation with<i>in vitro</i>results

Isabel González‐Álvarez, Carlos Fernández‐Teruel, Vicente G. Casabó‐Alós et al. · Biopharmaceutics & Drug Disposition · 2007 · 30 citations

A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin

Federica Grosso, Maurizio D’Incalci, Mirela Cartoafa et al. · Cancer Chemotherapy and Pharmacology · 2012 · 27 citations · Full text

Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer

Carlos Fernández‐Teruel, Ignacio Ferreira González, Iñaki F. Trocóniz et al. · Clinical Pharmacokinetics · 2018 · 26 citations

Medicine, Pharmacology, Clinical Trials +9